Session: SUN 234-256-Bone & Calcium Metabolism: Clinical Trials & Case Series
Poster Board SUN-239
Paolo Del Rio1, Diego Vicente2, Umberto Maestroni1, Anna Totaro1, Gian Maria Casoni Pattacini1, Itzhak Avital3, Alexander Stojadinovic2,4,5, Mario Sianesi1
1 Department of Surgery -University Hospital of Parma
2 Department of Surgery, Walter Reed National Military Medical Center, Bethesda, MD
3 Bon Secours Cancer Institute, Richmond, VA
4 United States Military Cancer Institute, Bethesda, MD
5 Uniformed Services University of the Health Sciences, Bethesda, MD
Background: Pre-operative imaging techniques for sporadic primary hyperparathyroidism (SPHPT) and intraoperative parathyroid hormone (ioPTH) have led to the wide spread use of minimally invasive surgical approaches.
Methods: In this prospective observational trial, 157 subjects with SPHPT and a preoperative diagnosis of parathyroid adenoma were treated with parathyroidectomy between January 2003 and November 2011. Subjects in group A were enrolled between January 2003 to September 2006, and underwent traditional parathyroidectomy with intraoperative frozen section and bilateral neck exploration. Subjects in group B were enrolled between September 2006 to November 2011, and underwent minimally invasive video-assisted parathyroidectomy (MIVAP) with ioPTH. Operative times and post-operative pain levels were compared between groups. Subjects were followed for a minimum of 6 months post-operatively and recurrence rates and complication rates were measured between groups.
Results: 81 patients were enrolled in group A, and 76 were enrolled in group B. Pre-operative evaluation demonstrated that the groups were statistically similar. Significantly decreased operative times (28min vs. 62min) and post-operative pain levels were noted in group B. Recurrence rates were similar between group A (3.7%) and group B (2.6%).
Conclusions: MIVAP with ioPTH demonstrated significantly improved operative times and post-operative pain levels, while maintaining equivalent recurrence rates.
Nothing to Disclose: PD, DV, UM, AT, GP, IA, AS, MS
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters